{
  "docId": "019de075-89b3-76e0-854f-751e522d63c5",
  "docSlug": "a1e66a21a5f72ac122dd8f79d63b40d9",
  "documentTitle": "Equillium | Investor Presentation Deck | 39 slides",
  "authorId": "equillium",
  "authorName": "Equillium",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 39,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Includes comparative data against Mogamulizumab (MAVORIC trial) and visual evidence of skin improvement.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-89b3-76e0-854f-751e522d63c5/20",
  "deckHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5",
  "deckJsonHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5.json",
  "deckAnchorHref": "/decks/019de075-89b3-76e0-854f-751e522d63c5#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.11,
        "w": 0.92,
        "x": 0.04,
        "y": 0.17
      },
      "kind": "callout",
      "text": "Favorable safety and tolerability demonstrated in 93 subjects across populations with compelling clinical activity observed in CTCL patients",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "10f5c592-d3fe-4784-96be-8a65d04d636f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.28,
        "w": 0.5,
        "x": 0.46,
        "y": 0.62
      },
      "kind": "image",
      "text": "Before/After clinical photos at Week 1 and Week 16",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "700322c5-c197-480a-8e3b-0169f589447c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.42,
        "x": 0.04,
        "y": 0.33
      },
      "kind": "list",
      "text": "Phase 1/2 MAD study in Cutaneous T Cell Lymphoma (n=30)\nHeavily pre-treated, refractory patient population\nDose escalation (0.5, 1, 2, 4mg/kg) with 4-week treatment/assessment period\nNo drug related SAEs, no DLTs\nDose-dependent PK/PD correlated with improved skin scores (mSWAT)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41a6c45f-cb83-4ff2-952d-09332488fcc7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.4,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "1) Kim et al., Lancet Oncol., 2018. 2) Querfeld et al., Blood, 2019. mSWAT = modified severity-weighted assessment. CTCL = Cutaneous T cell Lymphoma",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0756067a-5858-4e2f-944e-f77e22c998e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.5,
        "x": 0.46,
        "y": 0.33
      },
      "kind": "table",
      "text": "Response Rate in Stage IB/II Patients: MAVORIC Phase 3 Trial (Mogamulizumab n=68, 27.9%) vs EQ101 Phase 1/2 (EQ101 n=19, 42.1%)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1a9eb3cf-4465-42eb-9906-e4a807232a80",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "EQ101: Clinically Validated in Severe Dermatological Disease",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "78b06a6b-ac74-49b5-a653-a7b502e26e19",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "comparison_frame",
      "slug": null,
      "matchId": "8d875b3a-608e-4384-b260-1e97d0fda4bf",
      "evidence": "Direct comparison of response rates between MAVORIC trial and EQ101 trial",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}